SCHEMBL534550

SCHEMBL534550

O=C(P(=O)(O)O)P(=O)(O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.39
MMP8 P22894 5/20 0.39
MMP3 P08254 5/20 0.39
CA2 P00918 3/20 0.39
SLC34A1 Q06495 1/20 0.36
MMP1 P03956 5/20 0.33
MMP9 P14780 4/20 0.33
BLM P54132 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
LMNA P02545 2/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL7452703 0.95 MMP2 (0.37) MMP2MMP8MMP3CA2SLC34A1
Ammonia Solution, Strong SCHEMBL11583952 0.95 MMP2 (0.37) MMP2MMP8MMP3CA2SLC34A1
Ammonia Solution, Strong SCHEMBL11583945 0.95 MMP2 (0.37) MMP2MMP8MMP3CA2SLC34A1
SCHEMBL11623912 0.95 MMP2 (0.37) MMP2MMP8MMP3CA2SLC34A1
Water SCHEMBL7452695 0.95 MMP2 (0.37) MMP2MMP8MMP3CA2SLC34A1
SCHEMBL16383139 0.76 CA2 (0.47) MMP2MMP8MMP3CA2MMP1
SCHEMBL11054896 0.72
SCHEMBL31707295 0.72
Foscarnet SCHEMBL23633 0.70
Foscarnet SCHEMBL8647698 0.70 BLM (0.41) MMP2MMP8MMP3CA2SLC34A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731786-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID EXTENSION Pacific Biosciences of California, Inc. (US) 2026-04-29 EP claimed
EP-4705500-A2 REAGENT USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES DNA Script (FR) 2026-03-11 EP claimed
WO-2025006432-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID EXTENSION PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2025-01-02 WO claimed
US-20250002960-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID EXTENSION PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2025-01-02 US claimed
WO-2024227846-A2 REAGENT USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES DNA SCRIPT (FR) 2024-11-07 WO claimed
WO-2018158297-A1 CHK1 INHIBITION, SYNTHETIC LETHALITY AND CANCER TREATMENT THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2018-09-07 WO claimed
CN-106496268-A Phosphonyl-substituted methanol derivative and preparation method and application thereof 苏州大学 2017-03-15 CN claimed
US-20040236135-A1 Preparation and use of alpha-keto phosphonates SOUTHERN CALIFORNIA, UNIVERSITY OF 2004-11-25 US claimed
WO-2003011221-A2 PREPARATION AND USE OF α-KETO PHOSPHONATES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2003-02-13 WO claimed
EP-1097160-A4 PREPARATION AND USE OF ALPHA-KETO BISPHOSPHONATES UNIV SOUTHERN CALIFORNIA (US) 2002-06-12 EP claimed
US-6287840-B1 PEPTIDOMIMETICS; COUPLING, DEBLOCKING; ANTIARTHRITIC, ANTITUMOR, ANTICARCINOGENIC, AND ANTIMETASTASIS AGENTS; MUSCULAR DYSTROPHY, GLOMERULONEPHRITIS, MALARIA, ALZHEIMER*S DISEASE AXYS PHARMACEUTICALS, INC. 2001-09-11 US claimed
US-6281178-B1 PREVENT FILMING AND/OR STREAKING AFTER A SURFACE IS CLEANED WITH THE COMPOSTIONS. STEPAN COMPANY 2001-08-28 US claimed
EP-1097160-A1 PREPARATION AND USE OF ALPHA-KETO BISPHOSPHONATES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2001-05-09 EP claimed
WO-2000002889-A1 PREPARATION AND USE OF α-KETO BISPHOSPHONATES THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2000-01-20 WO claimed
WO-1998038202-A1 ANTIVIRAL PHOSPHONATE PRODRUGS OF NUCLEOSIDES AND NUCLEOSIDE ANALOGUES DANA-FARBER CANCER INSTITUTE (US) 1998-09-03 WO claimed
EP-0003007-B1 ALIPHATIC DERIVATIVES OF PHOSPHONOFORMIC ACID, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COMBATING VIRUS INFECTIONS Astra Läkemedel Aktiebolag (SE) 1982-04-07 EP claimed
US-4240920-A A SURFACTANT, A PEROXY BLEACH AND A PORPHINE BLEACH THE PROCTER & GAMBLE COMPANY (US) 1980-12-23 US claimed
EP-0003007-A2 Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections Astra Läkemedel Aktiebolag (SE) 1979-07-11 EP claimed
EP-4735621-A1 NUCLEIC ACID SYNTHESIS ON REUSABLE SUPPORT DNA Script (FR) 2026-05-06 EP disclosed
US-3932316-A PHOSPHATE-FREE THE PROCTER & GAMBLE COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236135-A1 Preparation and use of alpha-keto phosphonates PNKP, PFKFB1, PDXK MMP2 4817/4885MMP8 4522/4885MMP3 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.